crotononitrile: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 637921 |
| CHEMBL ID | 4748537 |
| CHEBI ID | 191223 |
| MeSH ID | M0097965 |
| Synonym |
|---|
| 2-butenenitrile, (e)- |
| e74gs2hl23 , |
| unii-e74gs2hl23 |
| (e)-ch3ch=chcn |
| (e)-2-butenenitrile |
| einecs 225-335-1 |
| beta-methylacrylonitrile |
| ai3-28717 |
| crotonique nitrile [french] |
| nsc 165574 |
| (2e)-but-2-enenitrile |
| 2-butenenitrile, (2e)- |
| crotonitrile |
| crotonic nitrile |
| 2-butenenitrile |
| 1-cyanopropene |
| crotononitrile |
| 4786-20-3 |
| crotonnitrile |
| 1-propenyl cyanide |
| but-2-enenitrile |
| CHEBI:191223 |
| (e)-but-2-enenitrile |
| 627-26-9 |
| AKOS000119979 |
| crotonique nitrile |
| crotonitril |
| crotono-nitrile |
| DTXSID0063604 |
| 1-cyano-1-propylene |
| .beta.-methylacrylonitrile |
| croton acid nitrile |
| trans-2-butenenitrile |
| C3132 |
| trans-crotononitrile |
| F0001-1268 |
| crotononitrile mix. cis and trans |
| crotononitrile, (e)- |
| mfcd00001935 |
| trans-crotononitrile (contains ca. 20% cis- isomer) |
| STL558687 |
| Q2672058 |
| BBL036260 |
| trans-but-2-enenitrile |
| trans-crotononitrile, >/=75%,contains ca. 20% cis-isomer |
| (2e)-2-butenenitrile |
| 2-butenenitrile, trans- |
| trans-.beta.-methylacrylonitrile |
| DTXSID801026544 |
| CHEMBL4748537 |
| PD168601 |
| 2-butenenitrile, mixture of cis and trans |
| Excerpt | Reference | Relevance |
|---|---|---|
| "5 LD50 doses of the nitriles by gavage and they were observed for 12 It for cholinomimetic and central nervous system effects." | ( Effect of dosing vehicle on the toxicity and metabolism of unsaturated aliphatic nitriles. Farooqui, MY; Piper, J; Tamez, A; Ybarra, B, ) | 0.13 |
| "Several alkylnitriles are toxic to sensory systems, including the vestibular system, through yet undefined mechanisms." | ( Differential role of CYP2E1-mediated metabolism in the lethal and vestibulotoxic effects of cis-crotononitrile in the mouse. Bayona, JM; Boadas-Vaello, P; Díez-Padrisa, N; Jover, E; Llorens, J, 2007) | 0.56 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "00 mmol/kg, 2-PN), which exhibit long-term dyskinesia, was examined on the metabolism of serotonin (5-HT) and dopamine (DA) in five brain regions of mice 1, 5, 12 and 35 days after dosing with CRN or 2-PN or vehicle (0." | ( Alterations in the metabolism of serotonin and dopamine in the central nervous system of mice displaying a persistent dyskinesia due to crotononitrile or 2-pentenenitrile. Hashimoto, K; Hayashi, M; Tanii, H, 1990) | 0.48 |
| " Pretreatment with 5,7-dihydroxytryptamine (5,7-DHT) suppressed the allylnitrile-induced head twitching, and decreased the contents of 5-HT and 5-HIAA in almost all areas of the brain throughout the observation period, as well as the ratio of 5-HIAA/5-HT in the medulla oblongata plus pons from 1 to 30 days after dosing with allylnitrile." | ( Involvement of noradrenergic and 5-hydroxytryptaminergic systems in allylnitrile-induced head twitching. Hashimoto, K; Huang, J; Tanii, H, 1993) | 0.29 |
| "The effect of dosing vehicle on toxicity and metabolism of unsaturated aliphatic nitriles was investigated in male Sprague-Dawley rats." | ( Effect of dosing vehicle on the toxicity and metabolism of unsaturated aliphatic nitriles. Farooqui, MY; Piper, J; Tamez, A; Ybarra, B, ) | 0.13 |
| " Rats in the high dosage groups exhibited a complete disappearance of the five waves of the auditory evoked-potentials." | ( The ototoxic effects induced in rats by treatment for 12 weeks with 2-butenenitrile, 3-butenenitrile and cis-2-pentenenitrile. Ban, M; Gagnaire, F; Langlais, C; Marignac, B, 2001) | 0.31 |
| " dosing schedule (2." | ( Butenenitriles have low axonopathic potential in the rat. Boadas-Vaello, P; Cutillas, B; Llorens, J; Saldaña-Ruíz, S; Soler-Martín, C, 2011) | 0.37 |
| Class | Description |
|---|---|
| nitrile | A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1687064 | Inhibition of Staphylococcus aureus MurA expressed in Escherichia coli assessed as residual activity at 100 uM using UNAG and PEP as substrate preincubated for 30 mins in presence of UNAG followed by PEP addition and measured after 15 mins by malachite gr | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | A road map for prioritizing warheads for cysteine targeting covalent inhibitors. |
| AID1687067 | Inhibition of recombinant cathepsin B (unknown origin) endopeptidase activity expressed in Escherichia coli assessed as residual activity at 100 uM using Z-RR-AMC as substrate preincubated for 30 mins under shaking in presence of 5 mM cysteine followed by | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | A road map for prioritizing warheads for cysteine targeting covalent inhibitors. |
| AID1687065 | Inhibition of Escherichia coli MurA assessed as residual activity at 100 uM using UNAG and PEP as substrate preincubated for 30 mins in presence of UNAG followed by PEP addition and measured after 15 mins by malachite green colorimetric assay relative to | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | A road map for prioritizing warheads for cysteine targeting covalent inhibitors. |
| AID1687069 | Inhibition of recombinant cathepsin X (unknown origin) expressed in Pichia pastoris assessed as residual activity at 100 uM using Abz-Fek(Dnp)-OH as substrate preincubated for 30 mins under shaking in presence of 5 mM cysteine followed by substrate additi | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | A road map for prioritizing warheads for cysteine targeting covalent inhibitors. |
| AID1687066 | Inhibition of Escherichia coli MurA assessed as residual activity at 100 uM using UNAG and PEP as substrate preincubated for 30 mins in presence of UNAG followed by PEP addition and measured after 15 mins in presence of 5 mM cysteine by malachite green co | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | A road map for prioritizing warheads for cysteine targeting covalent inhibitors. |
| AID1687068 | Inhibition of recombinant cathepsin B (unknown origin) exopeptidase activity expressed in Escherichia coli assessed as residual activity at 100 uM using Abz-GIVRAK(Dnp)-OH as substrate preincubated for 30 mins under shaking in presence of 5 mM cysteine fo | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | A road map for prioritizing warheads for cysteine targeting covalent inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (6.90) | 18.7374 |
| 1990's | 13 (44.83) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.01) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (6.25%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 30 (93.75%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||